Key facts: Arrowhead, Novartis finalize global collaboration; Swiss firms safe from U.S. drug tariffs

TradingView
2025.10.22 02:03
portai
I'm PortAI, I can summarize articles.

Arrowhead Pharmaceuticals has finalized a global license and collaboration agreement with Novartis, marking a significant partnership in the pharmaceutical sector.1Novartis and other Swiss pharma firms expect no impact from the 100% tariff on branded drug imports by the U.S., as they continue their expansion in the market.2

  • Arrowhead Pharmaceuticals has finalized a global license and collaboration agreement with Novartis, marking a significant partnership in the pharmaceutical sector.1
  • Novartis and other Swiss pharma firms expect no impact from the 100% tariff on branded drug imports by the U.S., as they continue their expansion in the market.2
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.